SCHEMBL5351636

SCHEMBL5351636

Nc1nc(NCC2CCN(S(=O)(=O)CCc3ccccc3)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 4/20 0.42
HDAC6 Q9UBN7 1/20 0.40
LMNA P02545 1/20 0.40
FAAH O00519 1/20 0.40
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ACHE P22303 1/20 0.38
TXNRD1 Q16881 1/20 0.38
TP53 P04637 1/20 0.37
GRIN2B Q13224 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MMP1 P03956 1/20 0.37
MMP7 P09237 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15972406 0.77 VCP (0.39) PRKCQLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL15972408 0.77 VCP (0.39) PRKCQLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL5351899 0.75 GRIN2B (0.58) HDAC6LMNAFAAHACHEGRIN2B
SCHEMBL5356278 0.75 NPY5R (0.56) LMNAMAPTALDH1A1
SCHEMBL5354940 0.75 FAAH (0.42) HDAC6LMNAFAAHMAPTACHE
SCHEMBL5355377 0.74 GRIN2B (0.49) HDAC6LMNAFAAHGRIN2B
SCHEMBL5348488 0.74 FAAH (0.42) PRKCQHDAC6LMNAFAAHSMN1; SMN2
SCHEMBL5348543 0.73 GRIN2B (0.62) HDAC6LMNAFAAHGRIN2B
SCHEMBL5354534 0.73 GRIN2B (0.58) HDAC6LMNAFAAHSMN1; SMN2ALDH1A1
SCHEMBL5759562 0.71 POLB (0.55) LMNASMN1; SMN2MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7053089-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2006-05-30 US disclosed
EP-1379520-B1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2006-04-26 EP disclosed
US-20040209889-A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists MERCK SHARP & DOHME CORP. 2004-10-21 US disclosed
US-20040204341-A1 Nr2b receptor antagonists for the treatment or prevention of migraines ALLEN CHRISTOPHER (US) 2004-10-14 US disclosed
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK SHARP & DOHME LLC 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209889-A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists GRIN1, GRIN2B, GRIN2A PRKCQ 2579/4885HDAC6 353/4885LMNA 4767/4885
US-20040204341-A1 Nr2b receptor antagonists for the treatment or prevention of migraines HTR1B, HTR2B, HTR1A PRKCQ 4108/4885HDAC6 1205/4885LMNA 1404/4885
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists GRIN1, GRIN2B, GRIN2A PRKCQ 2552/4885HDAC6 346/4885LMNA 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.